The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1.
Chen, J.L., Methot, J.L., Mitcheltree, M.J., Musacchio, A., Corcoran, E.B., Feng, G., Lammens, A., Maskos, K., Palte, R.L., Rickard, M.M., Otte, K.M., Mansueto, M.S., Venkat, S., Sondey, C., Thomsen, M., Lesburg, C.A., Fradera, X., Fell, M.J., DiMauro, E.F., Siliphaivanh, P.(2025) ACS Med Chem Lett 16: 811-818
- PubMed: 40365380 
- DOI: https://doi.org/10.1021/acsmedchemlett.5c00063
- Primary Citation of Related Structures:  
9MZX, 9MZY, 9MZZ - PubMed Abstract: 
Receptor-interacting protein kinase 1 (RIPK1) plays an essential role in necroptosis, a form of inflammatory, caspase-independent, programmed cell death. Allosteric inhibitors of RIPK1 have been shown to block necroptotic cell death and thus may offer potential therapeutic opportunities across a range of infectious, autoimmune, and neurodegenerative diseases. We report the structure-informed discovery of a novel series of bridged benzoazepine amides as part of our efforts to develop a CNS-penetrant small-molecule inhibitor of RIPK1 with a low projected oral human dose.
- Department of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts 02115, United States.
Organizational Affiliation: 
















